My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone (HGH)
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Intex Pharma Intex Pharma
Intex Stenabolic
Intex Stenabolic - Intex Pharma

Intex Stenabolic - Intex Pharma

Brand:
Intex Pharma
Category:
SARMs
Substance:
Stenabolic
Package:
60 tablets
Price:
€74.00 - €74.00
See options
Product Overview
Stenabolic (SR9009) was initially developed to act on REV-ERB receptors but has shown significant anticancer effects in prostate cancer through a distinct mechanism. Research reveals that SR9009 suppresses the LXRα/FOXM1 pathway, a critical driver of PCS1 prostate cancer aggressiveness. In both in vitro and in vivo models, SR9009 treatment reduces tumor size, decreases cell migration, and promotes apoptosis while sparing normal tissues. This selective action presents a novel approach to targeting prostate cancer without the adverse effects associated with conventional androgen-targeted therapies .
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Intex Stenabolic by Intex Pharma, consult with your doctor or healthcare professional.

Products
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Intex Stenabolic
Intex Pharma
International
€74.00
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Intex Stenabolic
Intex Pharma
UK
€74.00
Show more
Explore More Products
Reviews
Leave Review
FAQ
What subtype of prostate cancer does SR9009 target?
It is particularly effective against the highly aggressive PCS1 subtype.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Which pathway does SR9009 inhibit?
It disrupts the LXRα/FOXM1 pathway, a critical axis in prostate cancer progression.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Are there systemic side effects?
Animal studies indicate minimal systemic toxicity, suggesting a favorable safety profile.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.